MONITORING DURING
HORMONE THERAPY
Hormone therapies are highly effective but carry well-characterised risks โ regular monitoring detects complications early, allowing dose adjustments before irreversible harm occurs.
analyticsAt a Glance
- check_circleAromatase inhibitors cause bone loss โ DEXA scanning every 2 years and calcium/vitamin D supplementation are standard
- check_circleADT (for prostate cancer) causes metabolic syndrome โ PSA, testosterone, lipid panel, HbA1c, and DEXA every 3โ6 months
- check_circleTamoxifen increases endometrial cancer risk โ report abnormal bleeding immediately; annual pelvic ultrasound in post-menopausal women
- check_circleCDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib) require regular full blood count monitoring for neutropenia
Monitoring Schedule: Breast Cancer Hormone Therapy
Each breast cancer hormone therapy carries distinct monitoring requirements โ the schedule below reflects major guideline recommendations.
| Drug / Class | Test | Frequency | Why |
|---|---|---|---|
| Aromatase inhibitors (letrozole, anastrozole, exemestane) | DEXA bone density scan | Baseline + every 2 years | AIs cause accelerated bone loss โ osteoporosis develops in 15โ20% of long-term users |
| Aromatase inhibitors | Fasting cholesterol and lipid panel | Baseline + annually | AIs can worsen lipid profile โ particularly in post-menopausal women with baseline dyslipidaemia |
| Tamoxifen | Pelvic ultrasound + gynaecological review | Annually (post-menopausal) | Tamoxifen doubles endometrial cancer risk in post-menopausal women โ report any abnormal bleeding immediately |
| Tamoxifen | Liver function tests (LFTs) | Every 6 months | Rare hepatotoxicity โ screen baseline and periodically |
| CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib) | Full blood count (FBC) | Day 14โ15 of cycles 1โ2, then monthly | Neutropenia is the primary dose-limiting toxicity โ cycle 1 nadir on day 14โ15 |
| Ribociclib specifically | ECG (QTc interval) | Baseline + day 14 cycle 1 + as needed | Ribociclib uniquely prolongs QTc โ withhold if QTc >480ms |
| Fulvestrant / elacestrant | Liver function tests | Every 6 months | Monitor for hepatotoxicity โ rare but reported |
| Alpelisib (Piqray) | Fasting blood glucose and HbA1c | Weekly for first 2 months, then monthly | Hyperglycaemia occurs in >65% of patients โ diabetes management concurrent with treatment in many cases |
Monitoring Schedule: Prostate Cancer Hormone Therapy (ADT)
ADT (androgen deprivation therapy) causes metabolic syndrome, bone loss, and cardiovascular risk โ comprehensive monitoring is essential for long-term patients.
| Test | Frequency | What to Look For |
|---|---|---|
| PSA (prostate-specific antigen) | Every 3 months | PSA nadir (typically <0.2 on continuous ADT); PSA rise signals castration resistance |
| Testosterone level | Every 6 months | Testosterone should be <50 ng/dL (castrate level) on LHRH agonists โ confirm suppression is adequate |
| DEXA bone mineral density | Baseline + every 12โ24 months | ADT causes bone loss of 2โ8% per year โ bisphosphonates or denosumab indicated if T-score < -2.0 |
| Fasting lipid panel | Baseline + every 6โ12 months | ADT increases LDL and triglycerides โ statin therapy commonly required |
| Fasting glucose and HbA1c | Every 6 months | ADT increases insulin resistance and diabetes risk โ monitor for metabolic syndrome |
| Blood pressure | At each visit | Hypertension is common on ADT and worsened by enzalutamide/abiraterone |
| Full blood count | Every 6โ12 months | ADT causes mild normocytic anaemia โ typically not clinically significant unless combined with chemotherapy |
| Cardiovascular review (ECG, cardiology) | Annually or if symptoms | ADT increases QTc and cardiovascular event risk โ cardiology co-management for pre-existing cardiac disease |
Bone Health Management During Hormone Therapy
Both aromatase inhibitors (breast cancer) and ADT (prostate cancer) cause significant bone loss โ a structured bone health protocol prevents osteoporotic fractures.
- 1
Baseline DEXA Before Starting
DEXA scan at treatment initiation establishes baseline T-score โ essential for interpreting future changes and deciding whether bone-protecting treatment is needed from the start.
- 2
Calcium and Vitamin D Supplementation
All patients on AIs or ADT should take calcium 1000โ1200mg/day (dietary + supplement) and vitamin D 800โ1000 IU/day unless contraindicated โ these are the foundation of bone protection.
- 3
Repeat DEXA Every 1โ2 Years
Repeat scanning identifies patients developing bone loss requiring escalation to bisphosphonates (zoledronic acid) or denosumab before fracture occurs.
- 4
Weight-Bearing Exercise
30+ minutes of weight-bearing exercise (walking, resistance training) 3ร weekly reduces bone loss rate and improves metabolic syndrome parameters in ADT patients.
- 5
Bone-Protecting Therapy if T-score < -2.0
Zoledronic acid IV (every 6โ12 months) or denosumab SC (every 6 months) are indicated when T-score drops below -2.0 or fracture occurs despite basic supplementation.
Frequently Asked Questions
Monitoring Practicalities
Who should arrange DEXA bone density scanning โ my GP or my oncologist?
Either can order a DEXA scan โ typically the oncologist recommends it at baseline and the GP or endocrinologist coordinates ongoing monitoring. In many countries, oncologist-initiated DEXA referrals for patients on AIs or ADT are well-established. Ensure results are communicated to your oncologist for dose adjustment decisions.
My PSA has risen on ADT โ does that mean the cancer is back?
A rising PSA while testosterone is at castrate level (<50 ng/dL) defines castration-resistant prostate cancer (CRPC) โ which does not necessarily mean the cancer is uncontrolled, but does mean the treatment approach needs escalation. Rising PSA while testosterone is not suppressed means ADT is not working adequately and the LHRH agonist dose or timing should be reviewed. Always discuss PSA changes with your oncologist immediately.
Can monitoring be done in my home country while I'm on Indian generic drugs?
Yes โ CancerFax routinely coordinates home-country monitoring for patients who source drugs in India. You receive the monitoring schedule, get tests done locally, and CancerFax facilitates review by the Indian or Chinese treating oncologist. Results are communicated back with dosing recommendations for your home GP to implement.
More from the Hormone Therapy Resource Library
Explore drug guides, cost comparisons, and accessing hormone therapy abroad.
- โ Hormone Therapy for Cancer โ Complete Guide
- ADT Side Effects: Managing Bone Loss, Hot Flushes, and Fatigue
- CDK4/6 Inhibitors: Palbociclib, Ribociclib, Abemaciclib
- Aromatase Inhibitors: Letrozole, Anastrozole, Exemestane
- Androgen Deprivation Therapy for Prostate Cancer
- Accessing Hormone Therapy Abroad Through CancerFax
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination โ travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Manage Hormone Therapy Monitoring Abroad Through CancerFax
CancerFax coordinates monitoring test schedules, result review, and dose adjustment recommendations for patients on hormone therapy โ bridging between Indian or Chinese treating oncologists and patients in their home countries.
This content is for informational purposes only and does not constitute medical advice. Always consult your oncologist about your specific monitoring requirements.